Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 12/2021

01-12-2021 | Eosinophilic Esophagitis | Review

Eosinophilic Esophagitis and IgG4: Is There a Relationship?

Authors: Amanda H. Lim, Stephanie Wong, Nam Q. Nguyen

Published in: Digestive Diseases and Sciences | Issue 12/2021

Login to get access

Abstract

Our knowledge of the pathophysiology of eosinophilic esophagitis is constantly evolving. There is significant association between eosinophilic esophagitis and atopy; however, multiple studies have refuted the role of IgE in its pathogenesis. Instead, new data have demonstrated an elevated IgG4 level in patients with eosinophilic esophagitis. We review the current understanding of eosinophilic esophagitis pathogenesis and highlight the increasing evidence for the role of IgG4.
Literature
1.
Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022–1033 e10.PubMedCrossRef
2.
Spergel JM, Beausoleil JL, Mascarenhas M, Liacouras CA. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol. 2002;109(2):363–368.PubMedCrossRef
3.
Arias A, Lucendo AJ. Incidence and prevalence of eosinophilic oesophagitis increase continiously in adults and children in Central Spain: A 12-year population-based study. Dig Liver Dis. 2019;51(1):55–62.PubMedCrossRef
4.
Navarro P, Arias A, Arias-Gonzalez L, Laserna-Mendieta EJ, Ruiz-Ponce M, Lucendo AJ. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2019;49(9):1116–1125.PubMedCrossRef
5.
Mahesh VN, Holloway RH, Nguyen NQ. Changing epidemiology of food bolus impaction: Is eosinophilic esophagitis to blame? J Gastroenterol Hepatol. 2013;28(6):963–966.PubMedCrossRef
6.
Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230–1236 e1–2.PubMedCrossRef
7.
Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22 e1.CrossRef
8.
Mishra A, Schlotman J, Wang M, Rothenberg ME. Critical role for adaptive T cell immunity in experimental eosinophilic esophagitis in mice. J Leukoc Biol. 2007;81(4):916–924.PubMedCrossRef
9.
Philpott H, Nandurkar S, Royce SG, Thien F, Gibson PR. Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther. 2016;44(3):223–233.PubMedCrossRef
10.
Clayton F, Peterson K. Eosinophilic esophagitis: pathophysiology and definition. Gastrointest Endosc Clin N Am. 2018;28(1):1–14.PubMedCrossRef
11.
12.
Aceves SS. Remodeling and fibrosis in chronic eosinophil inflammation. Dig Dis. 2014;32(1–2):15–21.PubMedCrossRef
13.
Aceves SS, Newbury RO, Chen D, et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy. 2010;65(1):109–116.PubMedCrossRef
14.
Lieberman JA, Morotti RA, Konstantinou GN, Yershov O, Chehade M. Dietary therapy can reverse esophageal subepithelial fibrosis in patients with eosinophilic esophagitis: a historical cohort. Allergy. 2012;67(10):1299–1307.PubMedCrossRef
15.
Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59(1):21–30.PubMedCrossRef
16.
Blanchard C, Wang N, Rothenberg ME. Eosinophilic esophagitis: pathogenesis, genetics, and therapy. J Allergy Clin Immunol. 2006;118(5):1054–1059.PubMedCrossRef
17.
Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536–547.PubMedPubMedCentralCrossRef
18.
Sleiman PMA, March M, Hakonarson H. The genetic basis of eosinophilic esophagitis. Best Pract Res Clin Gastroenterol. 2015;29(5):701–707.PubMedCrossRef
19.
Molina-Infante J, Arias A, Alcedo J, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365–1372.PubMedCrossRef
20.
Spergel JM, Brown-Whitehorn TF, Cianferoni A, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol. 2012;130(2):461–467 e5.PubMedCrossRef
21.
Gonsalves N, Yang GY, Doerfler B, Ritz S, Ditto AM, Hirano I. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology. 2012;142(7):1451–1459 e1; quiz e14-51989.PubMedCrossRef
22.
Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158(6):1776–1786.PubMedCrossRef
23.
Warners MJ, Vlieg-Boerstra BJ, Bredenoord AJ. Elimination and elemental diet therapy in eosinophilic oesophagitis. Best Pract Res Clin Gastroenterol. 2015;29(5):793–803.PubMedCrossRef
24.
Peterson KA, Byrne KR, Vinson LA, et al. Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol. 2013;108(5):759–766.PubMedCrossRef
25.
Arias A, Gonzalez-Cervera J, Tenias JM, Lucendo AJ. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–1648.PubMedCrossRef
26.
Chehade M, Aceves SS. Food allergy and eosinophilic esophagitis. Curr Opin Allergy Clin Immunol. 2010;10(3):231–237.PubMedCrossRef
27.
Kagalwalla AF, Shah A, Li BU, et al. Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. J Pediatr Gastroenterol Nutr. 2011;53(2):145–149.PubMedCrossRef
28.
Wong J, Goodine S, Samela K, et al. Efficacy of dairy free diet and 6-food elimination diet as initial therapy for pediatric eosinophilic esophagitis: a retrospective single-center study. Pediatr Gastroenterol Hepatol Nutr. 2020;23(1):79–88.PubMedPubMedCentralCrossRef
29.
Lucendo AJ, Arias A, Gonzalez-Cervera J, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol. 2013;131(3):797–804.PubMedCrossRef
30.
Philpott H, Nandurkar S, Royce SG, Thien F, Gibson PR. A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016;43(9):985–993.PubMedCrossRef
31.
Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr. 2009;48(1):30–36.PubMedCrossRef
32.
Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol. 2005;3(12):1198–1206.PubMedCrossRef
33.
Gonsalves N. Food allergies and eosinophilic gastrointestinal illness. Gastroenterol Clin North Am. 2007;36(1):75–91, vi.PubMedCrossRef
34.
Kliewer K, Aceves S, Atkins D, et al. 817—Efficacy of 1-Food and 4-Food elimination diets for pediatric eosinophilic esophagitis in a randomized multi-site study. Gastroenterology 2019;156(6):S-172–S-3.CrossRef
35.
Kagalwalla AF, Wechsler JB, Amsden K, et al. Efficacy of a 4-food elimination diet for children with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15(11):1698–1707 e7.PubMedPubMedCentralCrossRef
36.
Kruszewski PG, Russo JM, Franciosi JP, Varni JW, Platts-Mills TA, Erwin EA. Prospective, comparative effectiveness trial of cow’s milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis. Dis Esophagus. 2016;29(4):377–384.PubMedCrossRef
37.
Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2012;129(6):1570–1578.PubMedPubMedCentralCrossRef
38.
Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2006;4(9):1097–1102.PubMedCrossRef
39.
Molina-Infante J, Arias A, Barrio J, Rodriguez-Sanchez J, Sanchez-Cazalilla M, Lucendo AJ. Four-food group elimination diet for adult eosinophilic esophagitis: a prospective multicenter study. J Allergy Clin Immunol. 2014;134(5):1093–1099 e1.PubMedCrossRef
40.
Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74–86 e15.PubMedCrossRef
41.
Hirano I, Safroneeva E, Roumet MC, et al. Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2020;51(8):750–759.PubMedCrossRef
42.
Schlag C, Miehlke S, Lucendo A, et al. Mo1129 Efficacy of budesonide orodispersible tablets for induction of remission in patients with active eosinophilic esophagitis: results from the 6-weeks open-label treatment phase of EOS-2 trial. Gastroenterology. 2019;156(6):S-715.CrossRef
43.
Lucendo AJ, De Rezende L, Comas C, Caballero T, Bellon T. Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis. Am J Gastroenterol. 2008;103(9):2184–2193.PubMedCrossRef
44.
Blanchard C, Mingler MK, Vicario M, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol. 2007;120(6):1292–1300.PubMedCrossRef
45.
Wong S, Smith G, Ruszkiewicz A, Nguyen N. Distinguishing gastroesophageal reflux disease and eosinophilic esophagitis in adults: The role of esophageal mucosal immunoglobulin G4: Distinguishing GORD and eosinophilic esophagitis with immunoglobulin G4. JGH Open. 2020.
46.
Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013;62(6):824–832.PubMedCrossRef
47.
Min JY, Ocampo CJ, Stevens WW, et al. Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: possible role of the nongastric H, K-ATPase. J Allergy Clin Immunol. 2017;139(1):130–141 e11.PubMedCrossRef
48.
Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–463 e1–3.PubMedCrossRef
49.
50.
Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology. 2020;158(1):111–122 e10.PubMedCrossRef
51.
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. Allergy. 2020;75:1023–1042.
52.
Hirano I, Furuta GT. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. Gastroenterology. 2020;158(4):840–851.PubMedCrossRef
53.
54.
Blanchard C, Stucke EM, Rodriguez-Jimenez B, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol. 2011;127(1):208–217 e1–7.PubMedPubMedCentralCrossRef
55.
56.
Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108(6):954–961.PubMedCrossRef
57.
Noti M, Wojno ED, Kim BS, et al. Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat Med. 2013;19(8):1005–1013.PubMedPubMedCentralCrossRef
58.
Clayton F, Fang JC, Gleich GJ, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014;147(3):602–609.PubMedCrossRef
59.
Molina-Infante J, Martin-Noguerol E, Alvarado-Arenas M, Porcel-Carreno SL, Jimenez-Timon S, Hernandez-Arbeiza FJ. Selective elimination diet based on skin testing has suboptimal efficacy for adult eosinophilic esophagitis. J Allergy Clin Immunol. 2012;130(5):1200–1202.PubMedCrossRef
60.
Weidlich S, Nennstiel S, Jesinghaus M, et al. IgG4 is elevated in eosinophilic esophagitis but not in gastroesophageal reflux disease patients. J Clin Gastroenterol. 2020;54(1):43–49.PubMedCrossRef
61.
Rosenberg CE, Mingler MK, Caldwell JM, et al. Esophageal IgG4 levels correlate with histopathologic and transcriptomic features in eosinophilic esophagitis. Allergy. 2018;73(9):1892–1901.PubMedCrossRef
62.
Rosenberg CMM, Morris D, Mukkada V, Putnam P, Rothenberg M. Esophageal IgG4 levels are elevated in pediatric eosinophilic esophagitis and correlate with esophageal histopathology including levels of eosinophils. J Allergy Clinical Immunol 2018;141:Supplement AB142.CrossRef
63.
Schuyler AJ, Wilson JM, Tripathi A, et al. Specific IgG4 antibodies to cow’s milk proteins in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2018;142(1):139–148 e12.PubMedPubMedCentralCrossRef
64.
65.
Wilson JM, Schuyler AJ, Tripathi A, Erwin EA, Commins SP, Platts-Mills TAE. IgG4 component allergens are preferentially increased in eosinophilic esophagitis as compared to patients with milk anaphylaxis or galactose-alpha-1,3-galactose allergy. J Allergy Clin Immunol. 2016;137(2):Supplement, AB199.CrossRef
66.
Schuyler AJ, Erwin EA, Oken E, Workman LJ, Gold DR, Platts-Mills TAE. The diagnostic utility of serum assays for total IgG4 and specific IgG4 antibodies to cow’s milk proteins in children with eosinophilic esophagitis: Comparison with an unselected birth cohort. J Allergy Clin Immunol. 2016;139:Supplement, AB48.CrossRef
67.
Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113(6):624–629.PubMedCrossRef
68.
Wright BL, Rank MA, Shim KS, Chinthrajah RS, Zhang W, Nadeau KC. Esophageal IgG4 and eosinophilic inflammation correlate in subjects undergoing peanut oral immunotherapy. J Allergy Clin Immunol. 2018;141:Supplement, AB404.CrossRef
69.
McGowan EC, Platts-Mills TAE, Wilson JM. Food allergy, eosinophilic esophagitis, and the enigma of IgG4. Ann Allergy Asthma Immunol. 2019;122(6):563–564.PubMedPubMedCentralCrossRef
70.
Trampert DC, Hubers LM, van de Graaf SFJ, Beuers U. On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1401–1409.PubMedCrossRef
71.
Varga EM, Kausar F, Aberer W, et al. Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol. 2013;131(5):1419–1421.PubMedCrossRef
72.
Dainichi T, Chow Z, Kabashima K. IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid. J Dermatol Sci. 2017;88(3):265–270.PubMedCrossRef
73.
Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013;110(51):20783–20788.PubMedPubMedCentralCrossRef
74.
Zukerberg L, Mahadevan K, Selig M, Deshpande V. Oesophageal intrasquamous IgG4 deposits: an adjunctive marker to distinguish eosinophilic oesophagitis from reflux oesophagitis. Histopathology. 2016;68(7):968–976.PubMedPubMedCentralCrossRef
75.
Culver EL, Sadler R, Bateman AC, et al. Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease. Clin Gastroenterol Hepatol. 2017;15(9):1444–1452 e6.PubMedPubMedCentralCrossRef
76.
Aalberse RC, Platts-Mills TA, Rispens T. The developmental history of IgE and IgG4 antibodies in relation to atopy, eosinophilic esophagitis, and the modified TH2 response. Curr Allergy Asthma Rep. 2016;16(6):45.PubMedPubMedCentralCrossRef
77.
Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol. 1983;130(2):722–726.PubMedCrossRef
78.
Jeal H, Draper A, Harris J, Taylor AN, Cullinan P, Jones M. Modified Th2 responses at high-dose exposures to allergen: using an occupational model. Am J Respir Crit Care Med. 2006;174(1):21–25.PubMedCrossRef
79.
van Neerven RJ, Wikborg T, Lund G, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol. 1999;163(5):2944–2952.PubMedCrossRef
80.
81.
82.
83.
Obiorah I, Hussain A, Palese C, Azumi N, Benjamin S, Ozdemirli M. IgG4-related disease involving the esophagus: a clinicopathological study. Dis Esophagus. 2017;30(12):1–7.PubMedCrossRef
84.
Khan S, Zhu LP, Jiang K, Liu W, Chen X, Wang BM. Immunoglobulin G4-Related Disease Manifesting as Isolated, Typical, and Nontypical Gastroesophageal Lesion: a Research of Literature Review. Digestion. 2020;101(5):506–521.PubMedCrossRef
85.
Shiokawa M, Kodama Y, Kuriyama K, et al. Pathogenicity of IgG in patients with IgG4-related disease. Gut. 2016;65(8):1322–1332.PubMedCrossRef
86.
Chien SJ, Silva KA, Kennedy VE, HogenEsch H, Sundberg JP. The pathogenesis of chronic eosinophilic esophagitis in SHARPIN-deficient mice. Exp Mol Pathol. 2015;99(3):460–467.PubMedPubMedCentralCrossRef
87.
Gunasekeera V, Mendall MA, Chan D, Kumar D. Treatment of Crohn’s Disease with an IgG4-Guided Exclusion Diet: a Randomized Controlled Trial. Dig Dis Sci. 2016;61(4):1148–1157.PubMedCrossRef
88.
Virdee K, Musset J, Baral M, Cronin C, Langland J. Food-specific IgG antibody-guided elimination diets followed by resolution of asthma symptoms and reduction in pharmacological interventions in two patients: a case report. Glob Adv Health Med. 2015;4(1):62–66.PubMedPubMedCentralCrossRef
89.
Zar S, Mincher L, Benson MJ, Kumar D. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol. 2005;40(7):800–807.PubMedCrossRef
90.
Schuyler A, Tripathi A, Kruszewski P, et al. Serum IgG4 Antibodies in Pediatric Subjects with Eosinophilic Esophagitis Treated with Cow’s Milk Elimination Diet or Swallowed Fluticasone: High Levels of Specific IgG4 to Cow’s Milk Components Despite Low to Negative IgE Antibodies. J Allergy Clin Immunol. 2016;137(2):AB232.CrossRef
Metadata
Title
Eosinophilic Esophagitis and IgG4: Is There a Relationship?
Authors
Amanda H. Lim
Stephanie Wong
Nam Q. Nguyen
Publication date
01-12-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06788-0

Other articles of this Issue 12/2021

Digestive Diseases and Sciences 12/2021 Go to the issue

Original Article

Circ_PGPEP1 Serves as a Sponge of miR-1297 to Promote Gastric Cancer Progression via Regulating E2F3

Original Article

Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis

Original Article

Regional Gastrointestinal Transit and Contractility Patterns Vary in Postural Orthostatic Tachycardia Syndrome (POTS)

Original Article

Mesenteric Lymph Duct Ligation Alleviates Acute Lung Injury Caused by Severe Acute Pancreatitis Through Inhibition of High Mobility Group Box 1-Induced Inflammation in Rats

Original Article

Curcumin Chemoprevention Reduces the Incidence of Braf Mutant Colorectal Cancer in a Preclinical Study

Original Article

Plasma Exosomal CircNEK9 Accelerates the Progression of Gastric Cancer via miR-409-3p/MAP7 Axis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits